HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
Hong Kong, Shanghai& Florham Park, NJ— Friday March 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX:13) today announces that it completed the rolling submission of a New Drug Application...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | China Health | Colorectal Cancer | Drugs & Pharmacology | Hong Kong Health | New Drug Applications